

Mathias Rosenfeldt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1269146/publications.pdf>

Version: 2024-02-01

37
papers

3,707
citations

331670

21
h-index

345221

36
g-index

44
all docs

44
docs citations

44
times ranked

6362
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of USP28 overcomes Cisplatin-resistance of squamous tumors by suppression of the Fanconi anemia pathway. <i>Cell Death and Differentiation</i> , 2022, 29, 568-584.	11.2	16
2	Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen-activated protein kinase pathway. <i>British Journal of Dermatology</i> , 2022, 186, 553-563.	1.5	3
3	<scp>Epstein-Barr-Virus</scp> infection patterns in nodular lymphocyte predominant Hodgkin lymphoma. <i>Histopathology</i> , 2022, , .	2.9	6
4	Acute systemic knockdown of <i>Atg7</i> is lethal and causes pancreatic destruction in shRNA transgenic mice. <i>Autophagy</i> , 2022, 18, 2880-2893.	9.1	3
5	Autophagy Blockage Reduces the Incidence of Pancreatic Ductal Adenocarcinoma in the Context of Mutant Trp53. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 785252.	3.7	2
6	The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming. <i>Cell Metabolism</i> , 2022, 34, 516-532.e11.	16.2	70
7	PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy. <i>Cell and Bioscience</i> , 2022, 12, 50.	4.8	9
8	A case of nodular lymphocyte predominant Hodgkin lymphoma with unexpected EBV-latency type. <i>Annals of Hematology</i> , 2021, 100, 2635-2637.	1.8	1
9	Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma. <i>Nature Cancer</i> , 2021, 2, 312-326.	13.2	50
10	LXR β activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. <i>Nature Cancer</i> , 2021, 2, 201-217.	13.2	27
11	Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 641618.	3.7	25
12	Loss of autophagy affects melanoma development in a manner dependent on PTEN status. <i>Cell Death and Differentiation</i> , 2021, 28, 1437-1439.	11.2	10
13	MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2021, 81, 4242-4256.	0.9	15
14	MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. <i>Nature Communications</i> , 2021, 12, 5066.	12.8	34
15	The histological and molecular spectrum of lipoblastoma: A case series with identification of three novel gene fusions by targeted RNA-sequencing. <i>Pathology Research and Practice</i> , 2021, 226, 153591.	2.3	4
16	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock 10 Tf,50 142 Td (edition 9.1 1,430	9.1	1,430
17	Mevalonate Pathway Provides Ubiquinone to Maintain Pyrimidine Synthesis and Survival in p53-Deficient Cancer Cells Exposed to Metabolic Stress. <i>Cancer Research</i> , 2020, 80, 189-203.	0.9	53
18	Maintaining protein stability of p63 via <scp>USP</scp> 28 is required by squamous cancer cells. <i>EMBO Molecular Medicine</i> , 2020, 12, e11101.	6.9	42

#	ARTICLE	IF	CITATIONS
19	LUBAC determines chemotherapy resistance in squamous cell lung cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 450-465.	8.5	57
20	Abstract 4377: Liver X receptor mediated lipotoxicity represents a treatment option for liver cancer. , 2019, , .		0
21	Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment. <i>Haematologica</i> , 2018, 103, 116-125.	3.5	48
22	Autophagy and cancer – insights from mouse models. <i>FEBS Journal</i> , 2018, 285, 792-808.	4.7	29
23	The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. <i>Oncogene</i> , 2018, 37, 5435-5450.	5.9	239
24	PTEN deficiency permits the formation of pancreatic cancer in the absence of autophagy. <i>Cell Death and Differentiation</i> , 2017, 24, 1303-1304.	11.2	23
25	CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1074-1081.	4.1	23
26	Loss of autophagy causes a synthetic lethal deficiency in DNA repair. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 773-778.	7.1	127
27	E2F1 drives chemotherapeutic drug resistance via ABCG2. <i>Oncogene</i> , 2014, 33, 4164-4172.	5.9	35
28	Elevated ROS Levels in Response to CD20-Targeting Enhance Senescence Entry after Immunochemotherapy in Human B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 2240-2240.	1.4	0
29	p53 status determines the role of autophagy in pancreatic tumour development. <i>Nature</i> , 2013, 504, 296-300.	27.8	614
30	Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1. <i>Cancer Discovery</i> , 2013, 3, 182-197.	9.4	117
31	Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. <i>Autophagy</i> , 2012, 8, 1175-1184.	9.1	69
32	Analysis of macroautophagy by immunohistochemistry. <i>Autophagy</i> , 2012, 8, 963-969.	9.1	67
33	The multiple roles of autophagy in cancer. <i>Carcinogenesis</i> , 2011, 32, 955-963.	2.8	262
34	Anti-CD20 Immunotherapy Augments the Chemotherapy-Induced Senescence Response In Human Lymphoma Cells. <i>Blood</i> , 2010, 116, 1827-1827.	1.4	2
35	The role of autophagy in tumour development and cancer therapy. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e36.	3.9	177
36	The organomercurial 4-aminophenylmercuric acetate, independent of matrix metalloproteinases, induces dose-dependent activation/ inhibition of platelet aggregation. <i>Thrombosis and Haemostasis</i> , 2005, 93, 326-330.	3.4	5

#	ARTICLE	IF	CITATIONS
37	Short-term treatment with indinavir fails to reduce the glucose requirement in a patient with malignant insulinoma. American Journal of Medicine, 2000, 108, 524.	1.5	0